Evidence map›Paper›PMID 39860125›Full record

ArticleMolecules (Basel, Switzerland)2025

Fluorescence Properties of Novel Multiresonant Indolocarbazole Derivatives for Deep-Blue OLEDs from Multiscale Computer Modelling.

Nikita O Dubinets, Andrey Yu Sosorev

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nikita O DubinetsEnikolopov Institute of Synthetic Polymeric Materials, Russian Academy of Science, Profsoyuznaya 70, Moscow 117393, Russia.ORCID 0000-0002-3287-7099
Andrey Yu SosorevEnikolopov Institute of Synthetic Polymeric Materials, Russian Academy of Science, Profsoyuznaya 70, Moscow 117393, Russia.ORCID 0000-0001-9343-5502

Funding

Ministry of Science and Higher Education of the Russian Federation FFSM-2022-0004
6 · The paper itself

Abstract

Multiresonant fluorophores are a novel class of organic luminophores with a narrow emission spectrum. They can yield organic light-emitting devices, e.g., OLEDs, with high colour purity. In this study, we applied DFT and multiscale modelling to predict the electronic and optical properties of several novel derivatives of indolocarbazole pSFIAc, which had recently shown a high potential in deep-blue OLEDs. We found that the addition of phenyls to a certain position of the pSFIAc core can considerably increase the fluorescent rate, leaving other properties (HOMO, LUMO, lowest excited singlet and lowest triplet states' energies) virtually unaffected. This can improve the efficiency and stability of deep-blue organic light-emitting devices; the suggested phenyl-substituted indolocarbazoles have been shown to be compatible with two popular anthracene-based hosts. On the contrary, the addition of phenyls to another positions of the core is detrimental for optoelectronic properties. QM/MM and QM/EFP calculations yielded negligible inhomogeneous broadening of the emission spectrum of the studied luminophores when embedded as dopants in anthracene-based hosts, predicting high colour purity of the corresponding devices. On the basis of the obtained results, we selected one novel multiresonant indolocarbazole derivative that is most promising for organic light-emitting devices. We anticipate the revealed structure-property relationships will facilitate the rational design of efficient materials for organic (opto)electronics.

Indexed as

DFTelectroluminescencefluorescencehost/dopantluminophoresmolecular designoptical gaporganic electronicsoscillator strengthQM/EFPQM/MM

Identifiers

PMID39860125
PMCPMC11767244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.